Bristol-Myers Squibb Rating Reiterated by Leerink Swann (BMY)
Bristol-Myers Squibb (NYSE:BMY)‘s stock had its “outperform” rating reiterated by research analysts at Leerink Swann in a report released on Thursday, Analyst Ratings Network.com reports. They currently have a $62.00 price target on the stock. Leerink Swann’s price objective would suggest a potential upside of 18.96% from the stock’s previous close.
A number of other analysts have also recently weighed in on BMY. Analysts at William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Thursday. Separately, analysts at BMO Capital Markets downgraded shares of Bristol-Myers Squibb from an “outperform” rating to a “market perform” rating in a research note on Thursday. They now have a $55.00 price target on the stock, down previously from $60.00. Finally, analysts at Jefferies Group raised their price target on shares of Bristol-Myers Squibb to $50.00 in a research note on Wednesday, May 7th. They now have a “hold” rating on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Buy” and a consensus target price of $56.15.
Shares of Bristol-Myers Squibb (NYSE:BMY) opened at 52.12 on Thursday. Bristol-Myers Squibb has a 52-week low of $41.11 and a 52-week high of $57.49. The stock has a 50-day moving average of $50.52 and a 200-day moving average of $52.20. The company has a market cap of $86.372 billion and a P/E ratio of 30.17.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Tuesday, April 29th. The company reported $0.46 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.43 by $0.03. The company had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.89 billion. During the same quarter in the prior year, the company posted $0.41 earnings per share. The company’s quarterly revenue was down .5% on a year-over-year basis. On average, analysts predict that Bristol-Myers Squibb will post $1.79 earnings per share for the current fiscal year.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.